The in vivo potential of TM treatment is illustrated in an elegant study by Ishida et al. employing the K14-HPV16/E2 transgenic mouse model of spontaneous cervical cancer, which showed that TM addition increases cisplatin-DNA adducts in tumors, but not in normal organs. The gene discussed is KRT14; the disease is cervical cancer.